XOMA-213 (LFA-102, X213) is a human monoclonal antibody (mAb) that specifically targets the PRLR/Prolactin Receptor. It inhibits hPRL-dependent growth of BaF3/hPRLR cells with an EC50 of 0.5 µg/mL. In models such as the Nb2-11-luc xenograft mouse and the DMBA-induced rat breast cancer model, XOMA-213 effectively suppresses PRLR signaling and tumor growth. This compound is applicable in research focused on breast cancer, hyperprolactinemia, and prostate cancer.
Target:
Estrogen Receptor/ERR
* VAT and and shipping costs not included. Errors and price changes excepted
